Short Bowel Syndrome Market Size, Share, Trends, Growth, Production, Consumption, Revenue and Forecast 2020 - 2027

Table of Contents

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Short Bowel Syndrome Market, By Drug Class

7.1. Short Bowel Syndrome Market, by Drug Class Type, 2020-2027

7.1.1. Glucagon-like Peptide-2 (GLP-2)

7.1.1.1. Market Revenue and Forecast (2016-2027)

7.1.2. Growth Hormone

7.1.2.1. Market Revenue and Forecast (2016-2027)

7.1.3. Glutamine

7.1.3.1. Market Revenue and Forecast (2016-2027)

7.1.4. Others

7.1.4.1. Market Revenue and Forecast (2016-2027) 

Chapter 8. Global Short Bowel Syndrome Market, Regional Estimates and Trend Forecast

8.1. North America

8.1.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.1.2. U.S.

8.1.3. Rest of North America

8.1.3.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.2. Europe

8.2.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.2.2. UK

8.2.2.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.2.3. France

8.2.3.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.2.4. Rest of Europe

8.2.4.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.3. APAC

8.3.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.3.2. India

8.3.2.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.3.3. China

8.3.3.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.3.4. Japan

8.3.4.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.3.5. Rest of APAC

8.3.5.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.4. MEA

8.4.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.4.2. GCC

8.4.2.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.4.3. North Africa

8.4.3.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.4.4. South Africa

8.4.4.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.4.5. Rest of MEA

8.4.5.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.5. Latin America

8.5.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.5.2. Brazil

8.5.2.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.5.3. Rest of LATAM

8.5.3.1. Market Revenue and Forecast, by Drug Class (2016-2027)

Chapter 9. Company Profiles

9.1. Shire plc (Takeda Pharmaceutical Company Limited)

9.1.1. Company Overview

9.1.2. Product Offerings

9.1.3. Financial Performance

9.1.4. Recent Initiatives

9.2. Zealand Pharma A/S

9.2.1. Company Overview

9.2.2. Product Offerings

9.2.3. Financial Performance

9.2.4. Recent Initiatives

9.3. Sancilio & Company, Inc.

9.3.1. Company Overview

9.3.2. Product Offerings

9.3.3. Financial Performance

9.3.4. Recent Initiatives

9.4. OxThera

9.4.1. Company Overview

9.4.2. Product Offerings

9.4.3. Financial Performance

9.4.4. Recent Initiatives

9.5. Nutrinia Ltd.

9.5.1. Company Overview

9.5.2. Product Offerings

9.5.3. Financial Performance

9.5.4. Recent Initiatives

9.6. Ardelyx, Inc.

9.6.1. Company Overview

9.6.2. Product Offerings

9.6.3. Financial Performance

9.6.4. Recent Initiatives

9.7. Emmaus Life Sciences, Inc.

9.7.1. Company Overview

9.7.2. Product Offerings

9.7.3. Financial Performance

9.7.4. Recent Initiatives

9.8. GLyPharma Therapeutic, Inc. (Pfizer Inc.)

9.8.1. Company Overview

9.8.2. Product Offerings

9.8.3. Financial Performance

9.8.4. Recent Initiatives

Chapter 10. Research Methodology

10.1. Primary Research

10.2. Secondary Research

10.3. Assumptions

Chapter 11. Appendix

11.1. About Us

11.2. Glossary of Terms